Quanterix (QTRX) to Release Quarterly Earnings on Tuesday

Quanterix (NASDAQ:QTRX - Get Free Report) is scheduled to announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Quanterix has set its FY 2024 guidance at EPS.Investors that wish to listen to the company's conference call can do so using this link.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.02). The business had revenue of $34.38 million during the quarter, compared to the consensus estimate of $34.19 million. Quanterix had a negative return on equity of 11.52% and a negative net margin of 30.71%. During the same period last year, the company earned ($0.16) earnings per share. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quanterix Stock Performance

QTRX traded up $0.87 during trading on Wednesday, reaching $15.39. The stock had a trading volume of 702,754 shares, compared to its average volume of 397,193. Quanterix has a 1-year low of $10.50 and a 1-year high of $29.70. The stock has a 50 day moving average of $12.74 and a two-hundred day moving average of $14.05.

Insider Activity

In other Quanterix news, Director David R. Walt bought 47,000 shares of Quanterix stock in a transaction dated Tuesday, August 20th. The stock was bought at an average price of $13.29 per share, for a total transaction of $624,630.00. Following the completion of the acquisition, the director now directly owns 1,487,342 shares of the company's stock, valued at approximately $19,766,775.18. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on QTRX. TD Cowen cut their target price on Quanterix from $17.00 to $15.00 and set a "hold" rating for the company in a research report on Friday, August 9th. Scotiabank cut their price objective on Quanterix from $32.00 to $28.00 and set a "sector outperform" rating for the company in a research report on Monday, August 12th. Finally, The Goldman Sachs Group cut their price objective on Quanterix from $35.00 to $24.00 and set a "buy" rating for the company in a research report on Tuesday, July 9th.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.